Document Detail


Mycophenolate mofetil therapy for refractory inflammatory bowel disease.
MedLine Citation:
PMID:  17924566     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Mycophenolate mofetil (MMF) is an immunomodulatory drug, and its use in inflammatory bowel disease has previously been reported. The aim of this study was to review the Leeds Colitis Clinic experience of the safety and efficacy of MMF in treating patients with refractory Crohn's disease (CD) and ulcerative colitis (UC). This is an extension of a previously published study from our center with a longer follow-up period and approximately twice the number of patients.
METHODS: A retrospective analysis was performed of the records of all patients treated with MMF for inflammatory bowel disease over a 5-year period.
RESULTS: Of 70 patients identified, 67 had previously been treated with azathioprine unsuccessfully. Seventeen of the 70 patients had been successfully maintained in remission with MMF for an average duration of 33 months. Treatment with MMF was discontinued for 53 patients, 17 because of side effects and 36 because they had not responded to the treatment.
CONCLUSIONS: In our series, 17 patients (24.3%) had a sustained steroid-free remission with MMF therapy. Nineteen patients (27%) experienced side effects, of which 17 (24.3% of the total group) had to discontinue therapy. An additional 36 (51.4%) required an escalation in medical therapy or surgery because of failure of the MMF therapy. MMF may have a role in the treatment of refractory inflammatory bowel disease, especially in patients who have previously failed standard therapies such as azathioprine.
Authors:
S Palaniappan; A C Ford; D Greer; S M Everett; D M Chalmers; A T R Axon; P J Hamlin
Related Documents :
23454446 - The prevalence of fluid associated with the iliotibial band in asymptomatic recreationa...
3544376 - Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recip...
25082956 - A randomized controlled trial studying efficacy and tolerance of a knee-ankle-foot orth...
11157146 - Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffu...
11558196 - Polymyalgia rheumatica and giant cell arteritis. avoiding management traps.
16550976 - Comparison of lornoxicam with tramadol in patient-controlled analgesia after gynecologi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Inflammatory bowel diseases     Volume:  13     ISSN:  1078-0998     ISO Abbreviation:  Inflamm. Bowel Dis.     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-11-12     Completed Date:  2008-02-14     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  9508162     Medline TA:  Inflamm Bowel Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1488-92     Citation Subset:  IM    
Affiliation:
Department of Gastroenterology, Leeds General Infirmary, Lees, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Azathioprine / therapeutic use
Colitis, Ulcerative / drug therapy*
Crohn Disease / drug therapy*
Female
Follow-Up Studies
Humans
Immunosuppressive Agents / adverse effects*,  therapeutic use*
Male
Middle Aged
Mycophenolic Acid / adverse effects,  analogs & derivatives*,  therapeutic use
Retrospective Studies
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 24280-93-1/Mycophenolic Acid; 446-86-6/Azathioprine; 9242ECW6R0/mycophenolate mofetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genome-wide expression profiling during protection from colitis by regulatory T cells.
Next Document:  Ectopia of meningeal fibroblasts and reactive gliosis in the cerebral cortex of the mouse model of m...